In July 2018, the Canadian Agency for Drugs and Technologies in Health (CADTH) recommended not to reimburse dupilumab.[1]

This is in contrast to the support and positive opinions conveyed by the fact that dupilumab (co-developed by Regeneron Pharmaceuticals and Sanofi) was approved in four major global regions (the US[2], the EU[3], Canada[4], and Japan[5]) within a ten-month period beginning March 2017, and followed swiftly by a positive Final Appraisal Determination (FAD) published by the National Institute for Health and Care Excellence (NICE) in June 2018. [6]

In late 2017, hope was sparked for patients and clinicians when Health Canada approved the agent for the treatment of adult patients with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. [4]

This negative decision from the CADTH has raised fears that patient access to this clinically-proven, effective treatment will be severely limited, especially for those relying on public drug plans and the ability for physicians to be freely available to prescribe this medication. [1]

For further information related to the first approval of dupilumab please visit Drugs[7], or to learn more about the overall development of dupilumab across all indications visit AdisInsight.[8]

 

Image credit: Gemma Evans Unsplash

Leave a Reply